Space Inventive

It costs $2.5 billion to bring a single drug to market. 9 out of 10 never make it.

And 80% of clinical trials fail to meet enrollment targets on time.

The math of drug development has been broken for decades. What's finally changing it? AI - and the results are no longer theoretical.

→ Stanford's Trial Pathfinder effectively doubled recruitment pools by intelligently relaxing eligibility criteria
→ AI-powered recruitment cut workload by 90% in a pediatric oncology study (NIH, 2023)
→ Insilico Medicine advanced the first AI-generated drug candidate into Phase II - faster than traditional processes ever could

Pharma-tech partnerships have grown 30% between 2022 and 2024. Pfizer, AstraZeneca, Sanofi, Eli Lilly - these aren't pilot programs anymore. They're operational commitments.

The question for pharma leaders in 2026 isn't whether to adopt AI in clinical development. It's how quickly - and where to start.

We wrote an honest breakdown: where AI is actually delivering, where it still falls short, and what your data infrastructure needs to look like before any of it works.

Read more → https://spaceinventive.com/blog/clinical-trials

Everyone’s buying the ticket.
Not everyone’s reaching the destination.

80% of companies have adopted AI.
Only 22% are actually seeing real ROI.

The gap isn’t technology. It’s clarity, ex*****on, and the right problems to solve.

AI doesn’t fail. Strategy does.

Ready to move from experimentation to impact? Let’s talk.
https://spaceinventive.com/contact